TRASTYVERE
OFFICIAL TITLE: CLINICAL BENEFIT OF THE TREATMENT WITH TRASTUZUMAB IN COMBINATION WITH LAPATINIB IN METASTATIC BREAST CANCER HER2 POSITIVE PATIENTS WHO HAS BEEN PREVIOUSLY TREATED WITH TRASTUZUMAB AND/OR LAPATINIB.
BLOG ARTICLES RELATED
SCIENTIFIC IMPACT
SABCS 2014 - DOWNLOAD THE POSTER
ECCO/ASCO 2014 - DOWNLOAD THE POSTER
SEOM 2014 - DOWNLOAD THE POSTER
SPAIN
(11)
CLINICAL TRIAL DETAILS
OBSERVATIONAL, RETROSPECTIVE AND MULTICENTER STUDY TO EVALUATE THE CLINICAL BENEFIT OF TRASTUZUMAB IN COMBINATION WITH LAPATINIB IN METASTATIC BREAST CANCER HER2 POSITIVE PATIENTS WHO HAS BEEN PREVIOUSLY TREATED WITH TRASTUZUMAB AND/OR LAPATINIB.
A RETROSPECTIVE, OBSERVATIONAL, NOT EPA, MULTICENTER STUDY TO EVALUATE THE CLINICAL BENEFIT OF TRASTUZUMAB IN COMBINATION WITH LAPATINIB IN METASTATIC BREAST CANCER HER2 POSITIVE PATIENTS WHO HAS BEEN PREVIOUSLY TREATED WITH TRASTUZUMAB AND/OR LAPATINIB BETWEEN JANUARY 2005 AND DECEMBER 2011.
TUMOR TYPE
PHASE
BREAST
(Her2-)
RETROSPECTIVE
111
14
Spain
Closing
N
SITES
COUNTRY
STATUS
TRASTYVERE SITES